Figure 3
Kaplan-Meier plots of survival by remission status in 142 consecutive patients receiving 131I-rituximab radioimmunotherapy for relapsed indolent lymphoma. CR/CRu indicates complete response; PR, partial response; and NR, no response.
Kaplan-Meier plots of survival by remission status in 142 consecutive patients receiving 131I-rituximab radioimmunotherapy for relapsed indolent lymphoma. CR/CRu indicates complete response; PR, partial response; and NR, no response.
